tbuckley/cabot-search huggingface dataset:
Radiation oncologist density and prostate cancer mortality.
Authors: S. Aneja, J. B. Yu
Journal: Journal of Clinical Oncology (2011)

72 Background: There exists a geographic variation among the distribution of radiation oncologists (RO). The goal of this study was to determine the effect of RO density (ROD) on prostate cancer (PC) mortality (PCM). Methods: Using county- level data from the 2008 Area Resource File, National Program for Cancer Registries, and US Centers for Disease Control, a multivariate regression model was constructed for PCM, controlling for county-level categorized ROD, demographics, socioeconomic status, and existing hospital facilities. Urologist and allergy/immunology density (UD and AID) were explored to assess whether the association with PCM was due to differences in regions with high medical specialist density or whether it was due to access to PC specific specialists. Results: There was a statistically significant reduction in PCM (reduction ranging from 9% to 29% p&lt;.001) associated with counties that possessed at least 1 RO. Moreover, increasing the county density to greater than 2 ROs per 100,000 people had a statistical significant reduction in PCM compared to having one RO (p&lt;.001). UD and AID were also associated with a reduction in PCM. Conclusions: The presence of a RO is associated with lowered PCM within that county, and increasing ROD does yield further improvements in PCM. Whether access to specialized medical care is an indicator of available health resources or directly influences PCM improvement is an important area of further study. [Table: see text] No significant financial relationships to disclose.
Evaluation of oral cyclophosphamide activity by CTC enumeration in patients with docetaxel-refractory castration-resistant metastatic prostate cancer: Potential utility in primary refractory disease.
Authors: O. B. Goodman, J. T. Symanowski, L. M. Fink, N. J. Vogelzang
Journal: Journal of Clinical Oncology (2011)

166 Background: Recent data suggest that circulating tumor cell (CTC) enumeration is a surrogate predictive endpoint for survival in metastatic castration-resistant prostate cancer (mCRPC). Data supporting the notion of changing therapy from docetaxel based on CTC numbers is limited in PC, due to a limited experience with second-line systemic therapies following docetaxel failure. Methods: Peripheral blood from patients receiving cyclophosphamide following progression on docetaxel was analyzed by CellSearch Methodology (Veridex, LLC; Warren NJ) enumerate CTC. Circulating tumor cells were enumerated prior to and at least three weeks following the initiation of cyclophosphamide. Patients were categorized as responsive, defined as a follow up CTC of &lt;5 cells or a greater than a 90% decline in counts between CTC determinations, or refractory (all others). Cyclophosphamide responsiveness was then correlated with docetaxel responsiveness using a Fisher-exact test. Results: Twenty two patients received oral cyclophosphamide therapy (50-150 mg/day). Of these, twelve (55%) were clinically primary docetaxel refractory, assessed by either clinical or PSAWG2 criteria while on docetaxel, and ten (45%) were initially responsive but subsequently progressed on docetaxel. Of the twelve patients who were primarily refractory to docetaxel, seven (58%) exhibited a cyclophosphamide response. In the majority of these cases, this response was durable with a complete disappearance of CTC. Conversely, only one patient (10%) who initially responded to docetaxel was sensitive to cyclophosphamide (P=0.031). Conclusions: Using a CTC endpoint cyclophosphamide appears to be active in patients initially refractory to docetaxel, but not those who initially responded. These data support the further evaluation of the potential for selective clinical utility of cyclophosphamide as second-line chemotherapy. [Table: see text]
Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience
Authors: Alessandra Mangia, Simone Susser, Valeria Piazzolla, Ernesto Agostinacchio, Giulio De Stefano, Vincenzo Palmieri, Giancarlo Spinzi, Immacolata Carraturo, Domenico Potenza, Ruggero Losappio, Andrea Arleo, Maria Miscio, Rosanna Santoro, Christoph Sarrazin, Massimiliano Copetti
Journal: Journal of Hepatology (2016)
Percutaneous irreversible electroporation (IRE) in the treatment of hepatocellular carcinoma (HCC) and metastatic colorectal cancer (mCRC) to the liver: A retrospective analysis of the University of Miami experience.
Authors: Arturo Loaiza-Bonilla, Katuska J Barbery, Evelyn Perez-Rojas, Tatiana Froud, Jose M Yrizarry, Ikechukwu Immanuel Akunyili, Caio Max S. Rocha Lima, Lynn G. Feun, Peter Joel Hosein, Govindarajan Narayanan
Journal: Journal of Clinical Oncology (2012)

272 Background: Percutaneous ablation and transarterial chemo- or radioembolization are commonly used in the treatment of HCC and mCRC to the liver. IRE using the Nanoknif is more versatile than other ablative modalities (such as RFA) in that tumors abutting vascular structures can be treated with IRE without compromise of the vessels or concern for the heat sink effect of nearby blood flow. Methods: We examined the records of patients (pts) referred for IRE for HCC and mCRC. The procedures were all done percutaneously under general anesthesia using a standard protocol. The primary endpoint was progression-free survival (PFS). Responses were assessed using the modified RECIST criteria. Results: Between 1/2010 and 8/2011, 49 pts underwent percutaneous ablation of unresectable HCC and mCRC liver tumors using IRE – 33 with HCC and 16 with mCRC. A total of 76 lesions were treated in 62 sessions; the median number of lesions treated per patient was 1 (range 1-4) and the median tumor size treated was 2.1cm (range 0.8-6). After IRE, 20 pts (41%) had a complete response (CR), 19 (39%) had a partial response and 10 (20%) had stable disease as their best response. The Kaplan-Meier estimated median PFS was 11.3 months (95% CI 9.6-12.9) for all pts, 11.6 months (95% CI 10.2-12.9) for HCC pts, and 10.4 months (95% CI 5.4-15.4) for mCRC patients. The one-year PFS was significantly higher for pts achieving a CR compared to those who did not achieve a CR (75% versus 59%, log rank p = 0.05). The number of liver lesions at baseline and size of the treated lesions were not associated with any differences in survival. The IRE was complicated in 6 pts (12%) by pneumothorax (2), pleural effusion (2), and atrial flutter/fibrillation during anesthesia (2). All pts recovered fully from these complications. One pt died within 1 month of the IRE due to disease progression. Conclusions: IRE of liver tumors is safe. The PFS rates for pretreated mCRC and unresectable HCC are promising. A complete lack of enhancement of the treated lesion on the post-IRE CT scan appears to be associated with longer survival.
Use of PG545, a heparanase inhibitor, to inhibit pancreatic cancer tumor cell proliferation and migration in vitro and in vivo.
Authors: Katherine Ostapoff, Niranjan Awasthi, Roderich Schwarz, Rolf A. Brekken
Journal: Journal of Clinical Oncology (2012)

234 Background: Pancreatic Ductal Adenocarcinoma (PDAC) is highly resistant to conventional chemotherapy, as result there is an ongoing search to find novel effective strategies. Resistance is due in part to the high proportion of stromal tissue within the primary tumor. This intricate ECM (extracellular matrix) includes heparan-sulfate glycosaminoglycans which participate in tumor progression, angiogenesis and metastasis. PG545 is a heparanase inhibitor developed to target these pathways. Methods: In vitro cell viability assays were performed using WST-1 reagent and migration was evaluated using T- scratch assay. Animal survival experiments were performed by intraperitoneal injection of AsPC-1 (0.75 x 10^6) cells. In vivo tumor growth experiments were performed by orthotopic injection of PanO2-HY (5x10^5) cells. Results: PG545 significantly inhibited proliferation of tumor cells (AsPC-1 and PanO2) and fibroblasts (WI-38). PG545 caused only a modest inhibition in endothelial cell (HUVECs) proliferation. Migration was significantly inhibited by 1 µM PG545 in AsPC-1 and PanO2 after 12 hours. In a metastatic model of pancreatic cancer, treatment with PG545 (10 mg/kg 1st week, 5 mg/kg 2nd week) improved survival (35 days) compared to saline (22 days) and gemcitabine (28 days). In an immunocompetent orthotopic model, mice treated with PG545 (5 mg/kg twice weekly) had significantly decreased tumor weights after 3 weeks of therapy (p=0.002). Total metastatic events were also reduced in PG545 compared to gemcitabine and control treatment in the PanO2 model. Conclusions: PG545 inhibits tumor cell proliferation and migration in vitro and prolongs survival and inhibits tumor growth in vivo. Additionally it inhibits metastasis in vivo. Further studies are underway to elucidate the mechanism of inhibition and changes to pancreatic tumor microenvironment.
Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML)
Authors: Dale L. Bixby, Anthony S. Stein, Amir T. Fathi, Tibor J. Kovacsovics, Moshe Y Levy, Harry P. Erba, Jeffrey E. Lancet, Anand P Jillella, Farhad Ravandi, Roland B. Walter, Eytan M. Stein, Stefan Faderl, Daniel J. DeAngelo, Phoenix Ho, Megan M. O'Meara, Jenna L Voellinger, Anjali Advani
Journal: Blood (2016)
Anti-Infectious Pathogen Specificity of Purified Monoclonal Immunoglobulins from Patients with MGUS and Multiple Myeloma
Authors: Adrien Bosseboeuf, Delphine Feron, Jean Harb, Cathy Charlier, Anne Tallet, Francois Girodon, Laurent Garderet, Cedric Rossi, Denis Caillot, Valéry Salle, Philippe Moreau, Pierre Weigel, Jean-Christophe Pages, Eric Piver, Edith Bigot-Corbel, Sylvie Hermouet
Journal: Blood (2016)
Initial experience of focal therapy for prostate cancer using I-125 seed implantation: Unilateral ablation for patients selected by extended biopsy and MRI findings.
Authors: K. Saito, K. Kihara, N. Numao, H. Masuda, T. Kijima, M. Tatokoro, F. Koga, Y. Fujii, K. Hayashi, H. Shibuya
Journal: Journal of Clinical Oncology (2011)

99 Background: Focal therapy for prostate cancer could be a minimally invasive therapeutic option with the preservation of genitourinary function to reduce treatment associated complication under the appropriate selection of patients. We have reported the good predict ability to unilateral prostate cancer by extended prostate biopsy combined with transperineal and transrectal approaches (Eur Urol supple, 2009). Among the candidate ablative, brachytherapy which has been proved as a definitive therapy and applied worldwide has been thought to have potential for focal ablation due to its ability of dose and location adjustment by seed implantation under real-time monitoring. Based on the findings, focal therapy with hemiablation using I-125 seed implantation has been started in our instituion. The aim of study is to describe the initial experience of focal therapy for patients selected by extended biopsy and MRI findings. Methods: The eligible criteria for focal therapy to prostate cancer are as follows. Clinical stage is T2a or less. The positive cores of cancer are proven within unilateral lobe by extended prostate biopsy. There was no cancerous lesion in contralateral lobe by MRI. Gleason score in positive cores was 3 + 4 or less. Maximum cancer length was less than 5 mm. PSA value is less than 10 ng/mL. On the treatment, I-125 seeds were implanted to ablate the unilateral lobe with 160 Gy of the prescription dose. The protocol has been approved by the institutional ethics commit. Results: At present, 3 patients were enrolled in this study and underwent focal therapy with written informed consents. In all three cases, I-125 seeds implanted (number od seeds: 43, 39, and 37) to unilateral lobe without severe acute complication such as acute urinary retention. In one case that has been followed over 3months among the initial three cases, PSA values decreased to 2.07 mg/ml at 3 months after the seed implantation. Conclusions: To our knowledge, this is the first report about focal therapy by brachytherapy with hemiablative technique. In our initail experience, severe treatment associated complication has not been observed. No significant financial relationships to disclose.
Integrated Immunological Analysis of the Bone Marrow Tumor Microenvironment in Myeloproliferative Neoplasms to Determine Potential Efficacy of Immune Checkpoint Blockade
Authors: Robert Orlowski, Alexander Huang, Mercy Gohil, James Mangan, Marissa Vignali, Ryan O Emerson, Harlan Robins, Erik Yusko, Martha S Jordan, Martin Carroll, D. Gary Gilliland, Elizabeth O Hexner
Journal: Blood (2015)
Validation of the Revised International Prognostic Scoring System (R-IPSS) for Patients with Myelodysplastic Syndromes: Therapeutic Implications.
Authors: Asmita Mishra, Najla H Al Ali, Maria Corrales-Yepez, Eric Padron, Ling Zhang, Pearlie K Epling-Burnette, Mohamed A Kharfan-Dabaja, Javier Pinilla-Ibarz, Bryan J Little, Jeffrey E Lancet, Alan F. List, Rami S. Komrokji
Journal: Blood (2012)
Body mass index in breast cancer subtypes.
Authors: I. Petekkaya, C. Arslan, E. Dogan, M. Solak, Ö. Keskin, N. Kertmen, Y. Y. Ozisik, K. Altundag
Journal: Journal of Clinical Oncology (2011)

1117 Background: Obesity is related with luminal type breast cancer. The aim of this study is to evaluate the association between body mass index (BMI) and breast cancer subtypes. Methods: 1,255 breast cancer patients diagnosed at our institution between 2006 and 2008 were retrospectively analyzed. BMI and hormone-receptor and HER-2 status at the time of diagnosis were recorded. Patients with BMI ≥ 25 were grouped as overweight/obese and BMI < 25 grouped as thin/normal. Data of the patients were retrospectively analyzed. Chi-square testing was used to evaluate categorical variables. Results: Median age of the patients was 51.9 (±11.8). Among patients with Luminal A subtype (estrogen receptor (ER), progesterone receptor (PR) positive and HER2-neu (HER2) negative), 259 (33.2%) were thin/normal, 522 (66.8%) were overweight/obese. Among patients with Luminal B subtype (ER, PR positive and HER-2 positive), 54 (36.2%) were thin/normal, 95 (63.8%) were overweight/obese. 58 (30.7%) patients were thin/normal and 131 (69.3%) patients were overweight/obese in triple-negative subtype. In HER-2 overexpressing subtype, 41 (30.1%) were thin/normal, 95 (69.8%) were overweight/obese. There were no statistically significant difference between BMI of patients among breast cancer subtypes (p=0.645). Conclusions: Previous studies suggest higher frequency of luminal subtype breast cancer in obese patients than control groups. In this study, we showed that there were no differences between BMI of Luminal A, B, HER2-overexpressing, and triple-negative breast cancers.
Effect of Second Mitochondria-Derived Activator of Caspases (Smac) Mimetic Compounds on Leukemic Cell Lines.
Authors: Federica Servida, Francesco Onida, Domenico Delia, Cinzia Scavullo, Daniele Lecis, Pierfausto Seneci, Carmelo Carlo Stella, Giorgio Lambertenghi Deliliers
Journal: Blood (2008)
Alemtuzumab (Campath IH) in Conditioning Therapy with Cyclophosphamide and Total Body Irradiation in Matched and Mismatched Unrelated Donor Transplantation of Children with Acute Lymphoblastic Leukaemia: A Report from 3 U.K. Centres.
Authors: Maged I. Gharib, Hayley M. Greenfield, Robert F. Wynn, Paul Veys, Paru Naik, Andrew M. Will, Jacqueline M. Cornish, Anthony Oakhill, Nicholas J. Goulden
Journal: Blood (2004)
Interventions to Improve Rates of Successful Extubation in Preterm Infants
Authors: Kristin N. Ferguson, Calum T. Roberts, Brett J. Manley, Peter G. Davis
Journal: JAMA Pediatrics (2016)

Clinicians aim to extubate preterm infants as early as possible, to minimize the risks of mechanical ventilation. Extubation is often unsuccessful owing to lung disease or inadequate respiratory drive.To conduct a systematic review and meta-analysis of interventions to improve rates of successful extubation in preterm infants.Searches were undertaken in PubMed and The Cochrane Library.The review was conducted using the methods of the Cochrane Collaboration and Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Studies were included if they were randomized clinical trials published in English, enrolled intubated preterm infants (born <37 weeks' gestation), and reported 1 or both of the primary outcomes.One thousand three hundred seventy-nine titles were screened independently by 2 investigators to assess need for full-text review. Disagreements were resolved via consensus of all authors. Where no Cochrane Review existed for an intervention, or not all identified studies were included, a new pooled analysis was performed.Primary outcomes were treatment failure or reintubation within 7 days of extubation.Fifty studies were eligible for inclusion. Continuous positive airway pressure reduced extubation failure in comparison with head-box oxygen (risk ratio [RR], 0.59; 95% CI, 0.48-0.72; number needed to treat [NNT], 6; 95% CI, 3-9). Nasal intermittent positive pressure ventilation was superior to continuous positive airway pressure in preventing extubation failure (RR, 0.70; 95% CI, 0.60-0.81; NNT, 8; 95% CI, 5-13). High-flow nasal cannula therapy and continuous positive airway pressure had similar efficacy (RR, 1.11; 95% CI, 0.84-1.47). Methylxanthines reduced extubation failure (RR, 0.48; 95% CI, 0.32-0.71; NNT, 4; 95% CI, 2-7) compared with placebo or no treatment. Corticosteroids (RR, 0.18; 95% CI, 0.04-0.97; NNT, 12; 95% CI, 6-100) and chest physiotherapy (RR, 0.32; 95% CI, 0.13-0.82; NNT, 15; 95% CI, 7-50) both reduced extubation failure rates but were associated with significant adverse effects. Doxapram did not aid successful extubation (RR, 0.80; 95% CI, 0.22-2.97).Preterm infants should be extubated to noninvasive respiratory support. Caffeine should be used routinely, while corticosteroids should be used judiciously, weighing up the competing risks of bronchopulmonary dysplasia and neurodevelopmental harm.
Imatinib efficacy by tumor genotype in Asian patients with metastatic or recurrent gastrointestinal stromal tumors (GISTs): A retrospective study of Korean GIST Study Group (KGSG).
Authors: H. J. Kang, M. Ryu, K. Kim, Y. S. Park, W. H. Kim, S. Im, S. H. Park, K. H. Lee, H. Song, Y. Kang
Journal: Journal of Clinical Oncology (2011)

10063 Background: Previous Asian studies in small scale suggested that imatinib efficacy might not be different by genotypes of tumor in Asian patients unlike the Western studies. This study was performed to assess the relationship between kinase mutation types of the tumor and treatment efficacy of imatinib in a large number of Korean patients with metastatic and recurrent GISTs. Methods: Clinical data were collected from 370 consecutive patients (pts) with metastatic or recurrent GISTs treated with first line imatinib between Feb. 2003 and Dec. 2007 at 20 institutions in Korea. Genotypes of the tumor were determined in 290 pts by direct sequencing of the genomic DNA for KIT exons 9, 11, 13, and 17 and PDGFRA exons 12, 14, and 18. Results: A total of 261 (90.0%) of 290 pts had mutations in KIT gene: 222 (76.6%) at exon 11, 35 (12.1%) at exon 9, and each two (0.7%) at exon 13, and 17. 4 pts (1.3%) had mutations in PDGFRA gene: 1 at exon 12, 3 at exon 18. 25 pts (8.6%) had no mutation in KIT or PDGFRA gene. Among the 235 pts with measurable lesions, there were 16 CRs (6.8%), 126 PRs (53.6%), and 86 SDs (36.6%), making the ORR 60.4%. Pts with KIT exon 9 mutation achieved significantly inferior response rate (11 of 30 pts, 36.7%) compared to those with KIT exon 11 mutation (112 of 176 pts, 63.6%; P=.007). Total 290 pts were assessable for progression-free survival (PFS). With a median follow-up of 42.8 months, pts with KIT exon 11 mutation (median 49.4 months) had significantly longer PFS than those with KIT exon 9 mutation (median 28.7 months, P=.001) or wild-type (median 33.1 months, P=.048). On the multivariate analyses, the genotype of the tumor (KIT exon 9 vs. KIT exon 11: HR=2.427, P=.003) remained independent prognostic factors for PFS as well as performance status (ECOG 2-3 vs. 0-1: HR=2.385, P=.005) and granulocyte counts (>7,500/µL vs. ≤7,500/µL: HR=3.756, P=.003). Conclusions: This study confirmed that imatinib efficacy was different by genotype of the GIST in Asian patients as well as Western patients. Patients with KIT exon 9 mutations had poorer response and inferior PFS at the standard dose of imatinib 400 mg per day and may benefit more with a higher dose of imatinib.
Cryopreservation of Peripheral Blood Stem Cells (PBSC) with Hydroxyethylstarch (HES) and Dimethylsulfoxide (DMSO) Results in Faster Granulocyte Recovery Than Using Dimethylsulfoxide Alone.
Authors: Wai Shun Chan, Michael Ma, Muhammad U.A. Bhatty, Robert Preti, Marie DeVito, Andrew L. Pecora, Michele L. Donato, Tatyana Feldman, Stuart L. Goldberg, Andre Goy, David S. Siegel, Scott D. Rowley
Journal: Blood (2007)
Multidisciplinary care of the breast cancer survivor: An innovative approach.
Authors: P. K. H. Morrow, T. B. Bevers, F. Zandstra, L. Russell
Journal: Journal of Clinical Oncology (2011)

206 Background: The Institute of Medicine recognizes cancer survivorship as an integral part of cancer care and advocates for appropriate survivorship care. We will describe the development of a Multidisciplinary Breast Survivorship Clinic (MBSC) and the metrics used to assess the program’s progress. Methods: To ensure effective integration of a MBSC into a major comprehensive cancer center, clinical leaders (in both the institution and breast leadership group) were approached and engaged in facilitating smooth transitioning of patients from the breast clinic to the survivorship domain. Eligibility criteria included: time of diagnosis ≤ 5 years and no evidence of active breast malignancy. After establishing these criteria, a multidisciplinary team (including endocrinologists, family physicians, medical oncologists, nurses, and research librarians) conducted an extensive literature review of evidence-based disease surveillance, risk reduction, screening for second cancers, and late effects of treatment modalities. These data became the basis of practice algorithms for invasive breast cancer, noninvasive breast cancer, and bone health. Treatment pathways included 4 domains of care: surveillance of the primary malignancy, risk reduction, cancer screening, and monitoring for late effects. The Passport Plan for Health (Passport) evolved from these domains. Results: Metrics used to assess the MBSC’s progress included number of survivors seen the clinic and number receiving Passports. Each patient is seen on the day of her mammogram (if clinically appropriate) and given a Passport on the initial visit, as well as subsequent visits. Between 9/1/2009-5/16/2011, 3594 patients participated in the Breast Survivorship Clinic. Of the 3584 patients seen in the survivorship clinic, 3435 patients received a completed Passport. Conclusions: The Passport strengths are to: facilitate communication with primary care physicians, communicate the care needs of the patient and designate the health care provider for their evaluation. Models of care such as the Multidisciplinary Breast Survivorship Clinic provide a rich environment to facilitate survivorship research aimed at assessing the optimal approach to the breast cancer survivor.